Hannah F. Bradford

Hannah F. Bradford

Auto-generated profile, based on publicly available information

Hannah F. Bradford

Infection and Immunity, University College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
HBHannah F. Bradford
Hannah F. Bradford
TMThomas C. R. McDonnell
Thomas C. R. McDonnell
ASAlexander Stewart
Alexander Stewart
ASAndrew Skelton
Andrew Skelton
JNJoseph Ng
Joseph Ng
CMClaudia Mauri
Claudia Mauri
Metabolic programming is important for B cell fate, but the bioenergetic requirement for regulatory B (Breg) cell differentiation and function is unknown. Here we show that Breg cell differentiation, unlike non-Breg cells, relies on mitochondrial electron transport and homeostatic levels of reactive oxygen species (ROS). Single-cell RNA sequencing analysis revealed that TXN, encoding the metabolic redox protein thioredoxin (Trx), is highly expressed by Breg cells, unlike Trx inhibitor TXNIP which was downregulated. Pharmacological inhibition or gene silencing of TXN resulted in mitochondrial membrane depolarization and increased ROS levels, selectively suppressing Breg cell differentiation and function while favoring pro-inflammatory B cell differentiation. Patients with systemic lupus erythematosus (SLE), characterized by Breg cell deficiencies, present with B cell mitochondrial membrane depolarization, elevated ROS and fewer Trx+ B cells. Exogenous Trx stimulation restored Breg cells and mitochondrial membrane polarization in SLE B cells to healthy B cell levels, indicating Trx insufficiency underlies Breg cell impairment in patients with SLE.

17 January 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
HBHannah F. Bradford
Hannah F. Bradford
LHLiis Haljasmägi
Liis Haljasmägi
MMMadhvi Menon
Madhvi Menon
TMThomas C.R. McDonnell
Thomas C.R. McDonnell
KSKarita Särekannu
Karita Särekannu
CMClaudia Mauri
Claudia Mauri
Systemic lupus erythematosus (SLE) is characterized by increased expression of type I interferon (IFN)-regulated genes in 50%-75% of patients. We report that out of 501 patients with SLE analyzed, 73 (14%) present autoantibodies against IFNα (anti-IFN-Abs). The presence of neutralizing-anti-IFN-Abs in 4.2% of patients inversely correlates with low circulating IFNα protein levels, inhibition of IFN-I downstream gene signatures, and inactive global disease score. Hallmarks of SLE pathogenesis, including increased immature, double-negative plasmablast B cell populations and reduction in regulatory B cell (Breg) frequencies, were normalized in patients with neutralizing anti-IFN-Abs compared with other patient groups. Immunoglobulin G (IgG) purified from sera of patients with SLE with neutralizing anti-IFN-Abs impedes CpGC-driven IFNα-dependent differentiation of B cells into immature B cells and plasmablasts, thus recapitulating the neutralizing effect of anti-IFN-Abs on B cell differentiation in vitro. Our findings highlight a role for neutralizing anti-IFN-Abs in controlling SLE pathogenesis and support the use of IFN-targeting therapies in patients with SLE lacking neutralizing-anti-IFN-Abs.

31 July 2024 in European Journal of Immunology
Verified
Journal Article
Open access
HBHannah F. Bradford
Hannah F. Bradford
CMClaudia Mauri
Claudia Mauri
Regulatory B cells (Bregs) are a functionally distinct B‐cell subset involved in the maintenance of homeostasis and inhibition of inflammation. Studies, from the last two decades, have increased our understanding of cellular and molecular mechanisms involved in their generation, function, and to a certain extent phenotype. Current research endeavours to unravel the causes and consequences of Breg defects in disease, with increasing evidence highlighting the relevance of Bregs in promoting tumorigenic responses. Here we provide historical and emerging findings of the significance of Bregs in autoimmunity and transplantation, and how these insights have translated into the cancer field.

24 February 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
HBHannah F. Bradford
Hannah F. Bradford
CLChristophe Jean Lalaurie
Christophe Jean Lalaurie
JGJayesh Gor
Jayesh Gor
XGXin Gao
Xin Gao
CPCharis Pericleous
Charis Pericleous
TMThomas Mcdonnell
Thomas Mcdonnell
β2-Glycoprotein I (β2GPI) is the main autoantigenic target of antiphospholipid syndrome, with antibodies leading to clinical manifestations. There are 2 known structural isomers of β2GPI: a J shape and a circular shape. The transition between these structures is incompletely understood, with the functional implications unknown. β2GPI is a substrate of the protease plasmin, which cleaves within the fifth domain of β2GPI, leading to altered cellular binding. Very little is currently known regarding the structure and function of this protein variant. We present the first comprehensive structural characterization of plasmin-clipped β2GPI and the associated implications for pathogenic antibody binding to this protein. To determine if cleavage of B2GPI by plasmin triggers structural change, and what this change may mean for antibody reactivity. β2GPI was purified using an adapted acid-free process from healthy control plasma and cleaved with plasmin. Cleavage was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Structural characterization was undertaken using dynamic light scattering, small-angle X-ray scattering, ion mobility mass spectrometry, and molecular dynamics simulation. Activity was tested using inhibition of β2GPI enzyme-linked immunosorbent assays with patient samples and cleaved β2GPI in the fluid phase and cellular binding by flow cytometry using human umbilical vein endothelial cells. Dynamic light scattering revealed a significantly smaller hydrodynamic radius for plasmin-clipped β2GPI (P = .0043). Small-angle X-ray scattering and molecular dynamics analysis indicated a novel S-like structure of β2GPI only present in the plasmin-clipped sample, while ion mobility mass spectrometry showed different structure distributions in plasmin-clipped compared with nonclipped β2GPI. The increased binding of autoantibodies was shown for plasmin-clipped β2GPI (P = .056), implying a greater exposure of pathogenic epitopes following cleavage. Cleavage of β2GPI by plasmin results in the production of a unique S-shaped structural conformation and higher patient antibody binding. This novel structure may increase the production of antibodies and explain the loss of binding to phospholipids described previously for plasmin-clipped β2GPI.

1 March 2025 in JHEP Reports
Verified
Journal Article
Open access
DFDouglas L. Fink
Douglas L. Fink
DEDavid Etoori
David Etoori
RHRobert Hill
Robert Hill
OIOrest Idilli
Orest Idilli
NKNikita Kartikapallil
Nikita Kartikapallil
UGUpkar S. Gill
Upkar S. Gill
Type one (T1) and three interferons (T3IFNs) are implicated in chronic hepatitis B (CHB) immunopathogenesis. IFN remains the only licenced immune modulating therapy for CHB. We measured the prevalence of auto-antibodies (auto-Abs) against T1 and T3IFNs to examine the hypothesis that they impact HBV control and treatment response, as highlighted by COVID-19. Our multi-centre retrospective longitudinal study accessed two CHB cohorts; auto-Ab levels and neutralisation status were measured against T1IFN and T3IFN. Associations were tested against HBV clinical parameters. Overall, 16.7% (46/276) of patients with CHB had any detectable anti-IFN auto-Abs at any time and 6.5% (18/276) anti-T3IFN auto-Abs, with a high incidence of PegIFNα-induced de novo auto-Abs (31.4%, 11/35). However, only a minority of auto-Ab-positive sera demonstrated neutralisation in vitro (4/46, 8.7%). Auto-Ab positivity correlated with higher median HBsAg levels (p = 0.0110). All individuals with detectable anti-T1IFN auto-Abs were PegIFNα non-responders. Non-neutralising anti-IFN auto-Abs are common in CHB and associate with higher median HBsAg levels. Further prospective study of anti-cytokine auto-Abs in CHB are required to characterise the association with long-term outcomes. HBV and PegIFNα individually may induce broad autoreactivity associated with dysregulated antiviral immune responses. Auto-Ab screening prior to PegIFNα treatment or other immunotherapies may play a critical role in predicting treatment responses.

10 December 2024 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
GMGuillem Montamat
Guillem Montamat
CMClaire E Meehan
Claire E Meehan
HBHannah F Bradford
Hannah F Bradford
RYReşit Yıldırım
Reşit Yıldırım
MGMaria Francisca Guimarães
Maria Francisca Guimarães
CMClaudia Mauri
Claudia Mauri
Introduction: Systemic lupus erythematosus (SLE) patients exhibit B-cell abnormalities. Although there are concerns about reduced antibody responses to SARS-CoV-2 vaccines, detailed data on B-cell-specific responses in SLE remain scarce. Understanding the responsiveness to novel vaccine antigens, and boosters number, is important to avoid unnecessarily prolonged isolation of immunocompromised individuals. We assessed humoral and antigen-specific B-cell subset responses, including changes in isotype switching, prior to and after several doses of SARS-CoV-2 vaccines. Methods: Blood samples were obtained prior to and after SARS-CoV-2 vaccination from cross-sectional and longitudinal cohorts of previously uninfected patients with SLE (n = 93). Healthy participants receiving SARS-CoV-2 vaccines were recruited as controls (n = 135). We measured serum antibody titres, their neutralizing capacity, and vaccine-specific memory B-cell subsets. Results: Impaired IgG, IgA, and neutralizing responses against the original and various SARS-CoV-2 variants were observed following two doses of vaccine in SLE patients. Follow-up booster doses increased humoral responses compared to baseline, but they remained lower, with poorer neutralisation capacity against most strains, compared to healthy individuals after three or more doses. Analysis of memory B-cell subsets in SLE patients revealed an increase of SARS-CoV-2-specific isotype unswitched IgM+ over SARS-CoV-2-specific isotype switched IgG+/IgA+ memory B-cells compared to healthy individuals. Culturing healthy naive B-cells with high levels of IFNα, a hallmark of SLE pathogenesis, prevented B-cells from switching to IgG under IgG-polarizing conditions. Conclusion: SLE patients’ protection against SARS-CoV-2 is overall impaired compared to healthy individuals and is associated with a class switch defect possibly due to chronic exposure of B-cells to IFNα.